Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Phase 2A Study to Examine the Preliminary Efficacy, Safety and PK of TAVO101 in Patients with Moderate to Severe Atopic Dermatitis (AD)

NCT06176040 is registered in ClinicalTrials.gov with Tavotek Biotherapeutics as lead sponsor.

NCT NCT06176040
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06176040 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Phase 2A Study to Examine the Preliminary Efficacy, Safety and PK of TAVO101 in Patients with Moderate to Severe Atopic Dermatitis (AD)
Lead sponsor
Tavotek Biotherapeutics
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 15, 2024
Completion date
June 15, 2025
Enrollment
20 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis